25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

VX1 (Vertex Pharmaceuticals Incorporated) Stock Analysis
Buy, Hold or Sell?

Let's analyze Vertex Pharmaceuticals Incorporated together

I guess you are interested in Vertex Pharmaceuticals Incorporated. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Vertex Pharmaceuticals Incorporated’s Financial Insights
  • 📈 Technical Analysis (TA) – Vertex Pharmaceuticals Incorporated’s Price Targets

I'm going to help you getting a better view of Vertex Pharmaceuticals Incorporated. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Vertex Pharmaceuticals Incorporated

I send you an email if I find something interesting about Vertex Pharmaceuticals Incorporated.

1. Quick Overview

1.1. Quick analysis of Vertex Pharmaceuticals Incorporated (30 sec.)










1.2. What can you expect buying and holding a share of Vertex Pharmaceuticals Incorporated? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€56.83
Expected worth in 1 year
€52.92
How sure are you?
93.9%

+ What do you gain per year?

Total Gains per Share
€-3.91
Return On Investment
-1.0%

For what price can you sell your share?

Current Price per Share
€376.25
Expected price per share
€368.15 - €444.00
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Vertex Pharmaceuticals Incorporated (5 min.)




Live pricePrice per Share (EOD)
€376.25
Intrinsic Value Per Share
€-17.12 - €-23.79
Total Value Per Share
€39.71 - €33.05

2.2. Growth of Vertex Pharmaceuticals Incorporated (5 min.)




Is Vertex Pharmaceuticals Incorporated growing?

Current yearPrevious yearGrowGrow %
How rich?$16.4b$15.9b$341.4m2.1%

How much money is Vertex Pharmaceuticals Incorporated making?

Current yearPrevious yearGrowGrow %
Making money-$133.8m$904.6m-$1b-775.8%
Net Profit Margin-6.5%36.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Vertex Pharmaceuticals Incorporated (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#7 / 890

Most Revenue
#9 / 890

Most Profit
#862 / 890

Most Efficient
#403 / 890
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Vertex Pharmaceuticals Incorporated?

Welcome investor! Vertex Pharmaceuticals Incorporated's management wants to use your money to grow the business. In return you get a share of Vertex Pharmaceuticals Incorporated.

First you should know what it really means to hold a share of Vertex Pharmaceuticals Incorporated. And how you can make/lose money.

Speculation

The Price per Share of Vertex Pharmaceuticals Incorporated is €376.25. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Vertex Pharmaceuticals Incorporated.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Vertex Pharmaceuticals Incorporated, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €56.83. Based on the TTM, the Book Value Change Per Share is €-0.98 per quarter. Based on the YOY, the Book Value Change Per Share is €3.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Vertex Pharmaceuticals Incorporated.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps3.550.9%-0.52-0.1%3.510.9%2.070.6%2.220.6%1.770.5%
Usd Book Value Change Per Share3.180.8%-1.10-0.3%3.530.9%2.040.5%2.020.5%1.930.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share3.180.8%-1.10-0.3%3.530.9%2.040.5%2.020.5%1.930.5%
Usd Price Per Share437.84-458.92-367.34-375.48-314.86-251.59-
Price to Earnings Ratio30.83-19.08-26.45-22.92-30.21-52.70-
Price-to-Total Gains Ratio137.53-90.78-112.51-94.92-109.82-92.85-
Price to Book Ratio6.86-7.32-5.91-6.48-6.68-9.66-
Price-to-Total Gains Ratio137.53-90.78-112.51-94.92-109.82-92.85-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share422.4535
Number of shares2
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-1.102.02
Usd Total Gains Per Share-1.102.02
Gains per Quarter (2 shares)-2.204.03
Gains per Year (2 shares)-8.7816.13
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-9-190166
20-18-2803222
30-26-3704838
40-35-4606554
50-44-5508170
60-53-6409786
70-61-730113102
80-70-820129118
90-79-910145134
100-88-1000161150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%31.02.00.093.9%31.02.00.093.9%
Book Value Change Per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%31.02.00.093.9%31.02.00.093.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.033.00.0%0.00.033.00.0%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%31.02.00.093.9%31.02.00.093.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Vertex Pharmaceuticals Incorporated compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.835-0.977+134%3.139-10%1.821+56%1.796+58%1.722+65%
Book Value Per Share--56.83556.439+1%55.277+3%51.607+10%42.766+33%30.324+87%
Current Ratio--2.6922.795-4%4.123-35%3.871-30%4.008-33%3.800-29%
Debt To Asset Ratio--0.2720.265+3%0.236+15%0.244+11%0.250+9%0.301-10%
Debt To Equity Ratio--0.3730.362+3%0.310+21%0.324+15%0.335+11%0.465-20%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--94796279390.400100142525404.438-5%79909730218.400+19%81821089851.346+16%68691531236.172+38%54949656523.152+73%
Eps--3.162-0.459+115%3.126+1%1.848+71%1.978+60%1.573+101%
Ev To Sales Ratio--9.14010.233-11%9.082+1%9.1760%8.786+4%10.209-10%
Free Cash Flow Per Share--1.704-0.842+149%2.832-40%1.796-5%2.007-15%2.007-15%
Free Cash Flow To Equity Per Share--0.349-2.133+712%2.346-85%1.184-71%1.298-73%1.298-73%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---23.789----------
Intrinsic Value_10Y_min---17.121----------
Intrinsic Value_1Y_max--5.808----------
Intrinsic Value_1Y_min--5.710----------
Intrinsic Value_3Y_max--11.207----------
Intrinsic Value_3Y_min--10.826----------
Intrinsic Value_5Y_max--9.080----------
Intrinsic Value_5Y_min--8.965----------
Market Cap96726723240.000-4%100248732830.400105364966264.438-5%84313670878.400+19%86136413451.346+16%72346643581.812+39%57769847586.861+74%
Net Profit Margin--0.314-0.065+121%0.366-14%0.224+40%0.283+11%0.294+7%
Operating Margin----0%0.232-100%0.241-100%0.313-100%0.287-100%
Operating Ratio--0.7630.740+3%0.743+3%0.705+8%0.706+8%0.841-9%
Pb Ratio6.620-4%6.8617.320-6%5.913+16%6.484+6%6.685+3%9.661-29%
Pe Ratio29.746-4%30.82919.076+62%26.452+17%22.919+35%30.211+2%52.699-41%
Price Per Share376.250-4%389.950408.725-5%327.163+19%334.413+17%280.426+39%224.070+74%
Price To Free Cash Flow Ratio55.200-4%57.21024.645+132%72.761-21%39.071+46%27.830+106%16.867+239%
Price To Total Gains Ratio132.699-4%137.53190.780+51%112.505+22%94.918+45%109.823+25%92.846+48%
Quick Ratio--0.8850.800+11%0.751+18%0.768+15%0.808+10%0.865+2%
Return On Assets--0.041-0.011+128%0.043-6%0.028+46%0.039+4%0.043-5%
Return On Equity--0.056-0.015+128%0.056-1%0.036+55%0.052+8%0.061-8%
Total Gains Per Share--2.835-0.977+134%3.139-10%1.821+56%1.796+58%1.722+65%
Usd Book Value--16405351882.75216336219784.304+0%15994783198.296+3%14924493679.928+10%12384235238.989+32%8778500075.847+87%
Usd Book Value Change Per Share--3.184-1.098+134%3.525-10%2.045+56%2.016+58%1.934+65%
Usd Book Value Per Share--63.81463.369+1%62.065+3%57.944+10%48.017+33%34.047+87%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--106437262499.541112440027524.102-5%89722645089.220+19%91868719685.091+16%77126851271.973+38%61697474344.195+73%
Usd Eps--3.550-0.516+115%3.510+1%2.075+71%2.221+60%1.766+101%
Usd Free Cash Flow--491872631.040-244436703.840+150%819512789.592-40%518707348.936-5%581264833.194-15%352281717.087+40%
Usd Free Cash Flow Per Share--1.913-0.945+149%3.180-40%2.017-5%2.254-15%2.254-15%
Usd Free Cash Flow To Equity Per Share--0.392-2.395+712%2.634-85%1.330-71%1.457-73%1.457-73%
Usd Market Cap108604764853.872-4%112559277221.973118303784121.710-5%94667389662.268+19%96713965023.171+16%81230811413.658+39%64863984870.527+74%
Usd Price Per Share422.454-4%437.836458.916-5%367.338+19%375.478+17%314.862+39%251.586+74%
Usd Profit--912763642.560-133865335.968+115%904665739.488+1%533695134.560+71%572838515.164+59%455332759.598+100%
Usd Revenue--2911246141.4402754311779.128+6%2466661265.376+18%2484356683.200+17%2179441740.021+34%1628605489.557+79%
Usd Total Gains Per Share--3.184-1.098+134%3.525-10%2.045+56%2.016+58%1.934+65%
 EOD+4 -4MRQTTM+23 -12YOY+16 -203Y+21 -155Y+22 -1410Y+25 -11

3.3 Fundamental Score

Let's check the fundamental score of Vertex Pharmaceuticals Incorporated based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1529.746
Price to Book Ratio (EOD)Between0-16.620
Net Profit Margin (MRQ)Greater than00.314
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.885
Current Ratio (MRQ)Greater than12.692
Debt to Asset Ratio (MRQ)Less than10.272
Debt to Equity Ratio (MRQ)Less than10.373
Return on Equity (MRQ)Greater than0.150.056
Return on Assets (MRQ)Greater than0.050.041
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Vertex Pharmaceuticals Incorporated based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.108
Ma 20Greater thanMa 50426.335
Ma 50Greater thanMa 100446.351
Ma 100Greater thanMa 200435.308
OpenGreater thanClose383.600
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2025-05-04 01:40:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Vertex Pharmaceuticals Incorporated earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Vertex Pharmaceuticals Incorporated to the Biotechnology industry mean.
  • A Net Profit Margin of 31.4% means that €0.31 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vertex Pharmaceuticals Incorporated:

  • The MRQ is 31.4%. The company is making a huge profit. +2
  • The TTM is -6.5%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ31.4%TTM-6.5%+37.8%
TTM-6.5%YOY36.6%-43.1%
TTM-6.5%5Y28.3%-34.8%
5Y28.3%10Y29.4%-1.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ31.4%-91.8%+123.2%
TTM-6.5%-183.9%+177.4%
YOY36.6%-195.7%+232.3%
3Y22.4%-245.0%+267.4%
5Y28.3%-351.3%+379.6%
10Y29.4%-492.7%+522.1%
4.3.1.2. Return on Assets

Shows how efficient Vertex Pharmaceuticals Incorporated is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Vertex Pharmaceuticals Incorporated to the Biotechnology industry mean.
  • 4.1% Return on Assets means that Vertex Pharmaceuticals Incorporated generated €0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vertex Pharmaceuticals Incorporated:

  • The MRQ is 4.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is -1.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ4.1%TTM-1.1%+5.2%
TTM-1.1%YOY4.3%-5.4%
TTM-1.1%5Y3.9%-5.0%
5Y3.9%10Y4.3%-0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1%-11.3%+15.4%
TTM-1.1%-11.5%+10.4%
YOY4.3%-11.5%+15.8%
3Y2.8%-11.9%+14.7%
5Y3.9%-12.5%+16.4%
10Y4.3%-14.2%+18.5%
4.3.1.3. Return on Equity

Shows how efficient Vertex Pharmaceuticals Incorporated is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Vertex Pharmaceuticals Incorporated to the Biotechnology industry mean.
  • 5.6% Return on Equity means Vertex Pharmaceuticals Incorporated generated €0.06 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vertex Pharmaceuticals Incorporated:

  • The MRQ is 5.6%. Using its investors money, the company is less efficient in making profit.
  • The TTM is -1.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ5.6%TTM-1.5%+7.1%
TTM-1.5%YOY5.6%-7.2%
TTM-1.5%5Y5.2%-6.7%
5Y5.2%10Y6.1%-0.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.6%-14.8%+20.4%
TTM-1.5%-15.2%+13.7%
YOY5.6%-15.1%+20.7%
3Y3.6%-17.6%+21.2%
5Y5.2%-18.1%+23.3%
10Y6.1%-20.1%+26.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Vertex Pharmaceuticals Incorporated.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Vertex Pharmaceuticals Incorporated is operating .

  • Measures how much profit Vertex Pharmaceuticals Incorporated makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Vertex Pharmaceuticals Incorporated to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vertex Pharmaceuticals Incorporated:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY23.2%-23.2%
TTM-5Y31.3%-31.3%
5Y31.3%10Y28.7%+2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--176.2%+176.2%
TTM--282.8%+282.8%
YOY23.2%-211.1%+234.3%
3Y24.1%-249.1%+273.2%
5Y31.3%-360.9%+392.2%
10Y28.7%-476.2%+504.9%
4.3.2.2. Operating Ratio

Measures how efficient Vertex Pharmaceuticals Incorporated is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.76 means that the operating costs are €0.76 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Vertex Pharmaceuticals Incorporated:

  • The MRQ is 0.763. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.740. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.763TTM0.740+0.024
TTM0.740YOY0.743-0.003
TTM0.7405Y0.706+0.034
5Y0.70610Y0.841-0.135
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7632.181-1.418
TTM0.7403.063-2.323
YOY0.7433.051-2.308
3Y0.7053.660-2.955
5Y0.7064.854-4.148
10Y0.8416.545-5.704
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Vertex Pharmaceuticals Incorporated.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Vertex Pharmaceuticals Incorporated is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.69 means the company has €2.69 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Vertex Pharmaceuticals Incorporated:

  • The MRQ is 2.692. The company is able to pay all its short-term debts. +1
  • The TTM is 2.795. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.692TTM2.795-0.103
TTM2.795YOY4.123-1.328
TTM2.7955Y4.008-1.213
5Y4.00810Y3.800+0.208
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6923.588-0.896
TTM2.7953.930-1.135
YOY4.1234.298-0.175
3Y3.8714.804-0.933
5Y4.0085.817-1.809
10Y3.8006.197-2.397
4.4.3.2. Quick Ratio

Measures if Vertex Pharmaceuticals Incorporated is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Vertex Pharmaceuticals Incorporated to the Biotechnology industry mean.
  • A Quick Ratio of 0.89 means the company can pay off €0.89 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vertex Pharmaceuticals Incorporated:

  • The MRQ is 0.885. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.800. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.885TTM0.800+0.086
TTM0.800YOY0.751+0.048
TTM0.8005Y0.808-0.009
5Y0.80810Y0.865-0.057
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8852.768-1.883
TTM0.8003.419-2.619
YOY0.7514.136-3.385
3Y0.7684.675-3.907
5Y0.8085.993-5.185
10Y0.8656.549-5.684
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Vertex Pharmaceuticals Incorporated.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Vertex Pharmaceuticals Incorporated assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Vertex Pharmaceuticals Incorporated to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.27 means that Vertex Pharmaceuticals Incorporated assets are financed with 27.2% credit (debt) and the remaining percentage (100% - 27.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Vertex Pharmaceuticals Incorporated:

  • The MRQ is 0.272. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.265. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.272TTM0.265+0.007
TTM0.265YOY0.236+0.028
TTM0.2655Y0.250+0.015
5Y0.25010Y0.301-0.051
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2720.342-0.070
TTM0.2650.342-0.077
YOY0.2360.331-0.095
3Y0.2440.330-0.086
5Y0.2500.359-0.109
10Y0.3010.382-0.081
4.5.4.2. Debt to Equity Ratio

Measures if Vertex Pharmaceuticals Incorporated is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Vertex Pharmaceuticals Incorporated to the Biotechnology industry mean.
  • A Debt to Equity ratio of 37.3% means that company has €0.37 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vertex Pharmaceuticals Incorporated:

  • The MRQ is 0.373. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.362. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.373TTM0.362+0.011
TTM0.362YOY0.310+0.052
TTM0.3625Y0.335+0.027
5Y0.33510Y0.465-0.130
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3730.408-0.035
TTM0.3620.427-0.065
YOY0.3100.409-0.099
3Y0.3240.430-0.106
5Y0.3350.447-0.112
10Y0.4650.497-0.032
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Vertex Pharmaceuticals Incorporated generates.

  • Above 15 is considered overpriced but always compare Vertex Pharmaceuticals Incorporated to the Biotechnology industry mean.
  • A PE ratio of 30.83 means the investor is paying €30.83 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vertex Pharmaceuticals Incorporated:

  • The EOD is 29.746. Based on the earnings, the company is overpriced. -1
  • The MRQ is 30.829. Based on the earnings, the company is overpriced. -1
  • The TTM is 19.076. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD29.746MRQ30.829-1.083
MRQ30.829TTM19.076+11.753
TTM19.076YOY26.452-7.375
TTM19.0765Y30.211-11.135
5Y30.21110Y52.699-22.487
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD29.746-1.711+31.457
MRQ30.829-2.407+33.236
TTM19.076-2.998+22.074
YOY26.452-3.336+29.788
3Y22.919-4.009+26.928
5Y30.211-6.310+36.521
10Y52.699-6.909+59.608
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Vertex Pharmaceuticals Incorporated:

  • The EOD is 55.200. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 57.210. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 24.645. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD55.200MRQ57.210-2.010
MRQ57.210TTM24.645+32.565
TTM24.645YOY72.761-48.116
TTM24.6455Y27.830-3.185
5Y27.83010Y16.867+10.963
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD55.200-2.379+57.579
MRQ57.210-3.217+60.427
TTM24.645-3.893+28.538
YOY72.761-4.283+77.044
3Y39.071-5.416+44.487
5Y27.830-8.278+36.108
10Y16.867-9.340+26.207
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Vertex Pharmaceuticals Incorporated is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 6.86 means the investor is paying €6.86 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Vertex Pharmaceuticals Incorporated:

  • The EOD is 6.620. Based on the equity, the company is overpriced. -1
  • The MRQ is 6.861. Based on the equity, the company is overpriced. -1
  • The TTM is 7.320. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.620MRQ6.861-0.241
MRQ6.861TTM7.320-0.459
TTM7.320YOY5.913+1.407
TTM7.3205Y6.685+0.635
5Y6.68510Y9.661-2.976
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.6201.696+4.924
MRQ6.8612.127+4.734
TTM7.3202.375+4.945
YOY5.9132.480+3.433
3Y6.4842.757+3.727
5Y6.6853.702+2.983
10Y9.6614.299+5.362
4.6.2. Total Gains per Share

2.4. Latest News of Vertex Pharmaceuticals Incorporated

Does Vertex Pharmaceuticals Incorporated still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Vertex Pharmaceuticals Incorporated to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-05-06
22:28
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?Read
2025-05-06
20:08
Uber-Pony AI partnership, EVgo boost, Vertex earnings missRead
2025-05-06
19:29
Vertex Pharmaceuticals (NasdaqGS:VRTX) Raises Guidance Despite Intangible Asset Impairment ChargeRead
2025-05-06
18:31
Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here’s Why.Read
2025-05-05
23:15
Vertex Pharmaceuticals (VRTX) Misses Q1 Earnings and Revenue EstimatesRead
2025-05-05
22:46
Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Sales Below Analyst Estimates In Q1 EarningsRead
2025-05-05
22:17
Vertex misses quarterly results on weaker-than-expected sales for cystic fibrosis drugRead
2025-05-05
22:09
Vertex: Q1 Earnings SnapshotRead
2025-05-05
22:01
Vertex Reports First Quarter 2025 Financial ResultsRead
2025-05-04
09:04
Earnings To Watch: Vertex Pharmaceuticals (VRTX) Reports Q1 Results TomorrowRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets22,533,200
Total Liabilities6,123,600
Total Stockholder Equity16,409,600
 As reported
Total Liabilities 6,123,600
Total Stockholder Equity+ 16,409,600
Total Assets = 22,533,200

Assets

Total Assets22,533,200
Total Current Assets9,596,400
Long-term Assets12,936,800
Total Current Assets
Cash And Cash Equivalents 4,569,600
Short-term Investments 1,546,300
Net Receivables 1,609,400
Inventory 1,205,400
Other Current Assets 76,400
Total Current Assets  (as reported)9,596,400
Total Current Assets  (calculated)9,007,100
+/- 589,300
Long-term Assets
Property Plant Equipment 2,584,600
Goodwill 1,088,000
Long Term Investments 5,107,900
Intangible Assets 825,900
Long-term Assets Other 999,300
Long-term Assets  (as reported)12,936,800
Long-term Assets  (calculated)10,605,700
+/- 2,331,100

Liabilities & Shareholders' Equity

Total Current Liabilities3,564,600
Long-term Liabilities2,559,000
Total Stockholder Equity16,409,600
Total Current Liabilities
Accounts payable 413,000
Other Current Liabilities 31,400
Total Current Liabilities  (as reported)3,564,600
Total Current Liabilities  (calculated)444,400
+/- 3,120,200
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,749,500
Long-term Liabilities Other 203,200
Long-term Liabilities  (as reported)2,559,000
Long-term Liabilities  (calculated)1,952,700
+/- 606,300
Total Stockholder Equity
Retained Earnings 9,606,800
Total Stockholder Equity (as reported)16,409,600
Total Stockholder Equity (calculated)9,606,800
+/- 6,802,800
Other
Capital Stock2,600
Common Stock Shares Outstanding 256,940
Net Invested Capital 16,409,600
Net Working Capital 6,031,800
Property Plant and Equipment Gross 3,649,400



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
2,896,787
2,946,703
3,285,594
3,198,325
3,546,014
3,952,974
4,335,386
4,620,840
6,245,898
6,543,114
7,033,471
7,514,553
8,318,465
8,893,201
10,216,367
11,301,633
11,751,808
12,115,059
12,221,686
12,618,745
13,432,500
14,256,100
15,582,200
16,706,400
18,150,900
18,974,200
20,349,200
21,726,200
22,730,200
23,917,400
20,132,100
22,240,200
22,533,200
22,533,20022,240,20020,132,10023,917,40022,730,20021,726,20020,349,20018,974,20018,150,90016,706,40015,582,20014,256,10013,432,50012,618,74512,221,68612,115,05911,751,80811,301,63310,216,3678,893,2018,318,4657,514,5537,033,4716,543,1146,245,8984,620,8404,335,3863,952,9743,546,0143,198,3253,285,5942,946,7032,896,787
   > Total Current Assets 
1,831,540
1,871,814
2,180,572
2,327,974
2,648,963
3,041,116
3,407,423
3,686,611
3,843,109
4,183,039
4,710,968
4,777,094
4,822,829
5,222,752
6,694,320
7,458,456
8,133,379
8,539,307
8,457,514
8,852,540
9,560,600
10,361,300
11,503,500
12,271,000
13,234,800
12,965,700
13,872,900
14,695,800
14,144,200
13,288,700
8,941,600
9,804,100
9,596,400
9,596,4009,804,1008,941,60013,288,70014,144,20014,695,80013,872,90012,965,70013,234,80012,271,00011,503,50010,361,3009,560,6008,852,5408,457,5148,539,3078,133,3797,458,4566,694,3205,222,7524,822,8294,777,0944,710,9684,183,0393,843,1093,686,6113,407,4233,041,1162,648,9632,327,9742,180,5721,871,8141,831,540
       Cash And Cash Equivalents 
1,231,707
1,048,243
1,223,130
1,384,966
1,665,412
1,995,893
2,145,359
2,478,302
2,650,134
2,893,885
3,294,684
3,397,941
3,109,322
3,593,412
4,831,332
5,358,087
5,988,187
6,304,330
6,063,678
6,275,698
6,795,000
7,600,100
8,702,200
9,171,500
10,504,000
9,289,900
10,151,100
11,110,200
10,369,100
9,158,000
4,580,100
5,239,200
4,569,600
4,569,6005,239,2004,580,1009,158,00010,369,10011,110,20010,151,1009,289,90010,504,0009,171,5008,702,2007,600,1006,795,0006,275,6986,063,6786,304,3305,988,1875,358,0874,831,3323,593,4123,109,3223,397,9413,294,6842,893,8852,650,1342,478,3022,145,3591,995,8931,665,4121,384,9661,223,1301,048,2431,231,707
       Short-term Investments 
250,612
405,103
445,520
427,282
423,254
481,124
622,396
577,583
518,108
584,150
656,538
598,390
698,972
596,984
619,437
792,971
670,710
619,638
644,315
685,187
729,900
638,000
551,200
599,200
274,500
1,124,200
1,085,200
818,000
849,200
1,013,300
1,215,400
1,285,300
1,546,300
1,546,3001,285,3001,215,4001,013,300849,200818,0001,085,2001,124,200274,500599,200551,200638,000729,900685,187644,315619,638670,710792,971619,437596,984698,972598,390656,538584,150518,108577,583622,396481,124423,254427,282445,520405,103250,612
       Net Receivables 
201,083
207,955
247,949
263,493
384,490
327,294
393,439
379,755
452,529
438,297
464,900
443,315
633,518
845,269
791,768
791,917
885,352
977,551
929,142
1,100,372
1,136,800
1,292,800
1,332,900
1,385,200
1,442,200
1,547,800
1,556,200
1,538,700
1,563,400
1,793,200
1,656,100
1,750,600
1,609,400
1,609,4001,750,6001,656,1001,793,2001,563,4001,538,7001,556,2001,547,8001,442,2001,385,2001,332,9001,292,8001,136,8001,100,372929,142977,551885,352791,917791,768845,269633,518443,315464,900438,297452,529379,755393,439327,294384,490263,493247,949207,955201,083
       Inventory 
77,604
82,020
92,263
98,192
111,830
117,346
115,025
124,150
124,360
136,698
143,017
162,306
167,502
187,087
219,218
245,460
280,777
298,863
321,620
333,456
353,100
338,900
367,700
388,200
460,600
535,100
603,500
688,700
738,800
813,100
914,600
1,079,800
1,205,400
1,205,4001,079,800914,600813,100738,800688,700603,500535,100460,600388,200367,700338,900353,100333,456321,620298,863280,777245,460219,218187,087167,502162,306143,017136,698124,360124,150115,025117,346111,83098,19292,26382,02077,604
       Other Current Assets 
70,534
128,493
65,613
1,845
1,502
10,490
19,727
22,652
23,933
25,460
20,177
33,903
17,729
33,986
12,422
3,571
658
15,616
16,935
38,815
187,200
61,100
120,800
197,100
121,900
25,200
9,100
540,200
84,300
511,100
575,400
449,200
76,400
76,400449,200575,400511,10084,300540,2009,10025,200121,900197,100120,80061,100187,20038,81516,93515,6166583,57112,42233,98617,72933,90320,17725,46023,93322,65219,72710,4901,5021,84565,613128,49370,534
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
2,360,075
2,322,503
2,737,459
3,495,636
3,446,801
3,522,047
3,843,177
3,926,782
3,914,677
3,764,172
4,224,032
4,417,700
3,894,800
4,078,700
4,435,400
5,469,600
6,008,500
6,476,300
7,030,400
8,586,000
10,628,700
11,190,500
12,436,100
12,936,800
12,936,80012,436,10011,190,50010,628,7008,586,0007,030,4006,476,3006,008,5005,469,6004,435,4004,078,7003,894,8004,417,7004,224,0323,764,1723,914,6773,926,7823,843,1773,522,0473,446,8013,495,6362,737,4592,322,5032,360,075000000000
       Property Plant Equipment 
698,362
708,395
740,103
759,978
789,437
800,670
815,928
808,352
812,005
803,132
789,162
794,438
833,282
736,303
728,357
920,913
1,284,098
1,308,442
1,338,107
1,354,690
1,424,400
1,436,400
1,418,400
1,118,700
1,108,400
1,448,000
1,446,700
1,434,500
1,452,900
1,485,700
1,770,700
2,513,900
2,584,600
2,584,6002,513,9001,770,7001,485,7001,452,9001,434,5001,446,7001,448,0001,108,4001,118,7001,418,4001,436,4001,424,4001,354,6901,338,1071,308,4421,284,098920,913728,357736,303833,282794,438789,162803,132812,005808,352815,928800,670789,437759,978740,103708,395698,362
       Goodwill 
50,384
50,384
50,384
50,384
50,384
50,384
50,384
50,384
50,384
50,384
50,384
447,525
1,002,158
1,002,158
1,002,158
1,002,158
1,402,158
1,402,158
1,002,158
1,402,158
1,402,200
1,002,200
1,002,200
1,075,200
1,088,000
1,088,000
1,088,000
1,088,000
1,088,000
1,088,000
1,088,000
1,088,000
1,088,000
1,088,0001,088,0001,088,0001,088,0001,088,0001,088,0001,088,0001,088,0001,088,0001,075,2001,002,2001,002,2001,402,2001,402,1581,002,1581,402,1581,402,1581,002,1581,002,1581,002,1581,002,158447,52550,38450,38450,38450,38450,38450,38450,38450,38450,38450,38450,384
       Long Term Investments 
20,276
20,276
20,252
20,447
20,447
0
0
36,700
13,600
13,600
33,600
40,800
60,800
0
0
0
0
0
0
0
0
0
0
0
112,200
1,081,500
1,357,300
1,700,000
2,497,800
4,381,400
4,393,100
4,703,500
5,107,900
5,107,9004,703,5004,393,1004,381,4002,497,8001,700,0001,357,3001,081,500112,2000000000000060,80040,80033,60013,60013,60036,7000020,44720,44720,25220,27620,276
       Intangible Assets 
284,340
284,340
284,340
29,000
29,000
29,000
29,000
29,000
50,384
0
0
0
400,000
400,000
400,000
400,000
400,000
400,000
400,000
400,000
400,000
400,000
387,000
603,600
603,600
603,600
603,600
603,600
839,900
834,900
837,500
831,600
825,900
825,900831,600837,500834,900839,900603,600603,600603,600603,600603,600387,000400,000400,000400,000400,000400,000400,000400,000400,000400,000400,00000050,38429,00029,00029,00029,00029,000284,340284,340284,340
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
39,041
57,766
79,985
157,583
160,635
176,564
372,290
683,311
710,506
71,099
845,688
986,900
110,700
127,300
132,500
1,422,700
427,500
442,700
475,200
895,300
875,700
915,600
990,200
999,300
999,300990,200915,600875,700895,300475,200442,700427,5001,422,700132,500127,300110,700986,900845,68871,099710,506683,311372,290176,564160,635157,58379,98557,76639,041000000000
> Total Liabilities 
1,740,205
1,446,695
1,418,363
1,395,081
1,503,708
1,522,153
1,620,503
1,686,359
1,810,695
1,819,801
1,963,506
2,261,159
2,233,221
2,431,547
2,697,125
3,168,160
3,064,993
3,134,805
3,025,290
3,088,037
3,332,500
3,349,100
3,648,700
3,676,800
4,238,200
4,541,900
4,879,000
5,213,400
5,149,800
5,370,800
5,357,400
6,609,300
6,123,600
6,123,6006,609,3005,357,4005,370,8005,149,8005,213,4004,879,0004,541,9004,238,2003,676,8003,648,7003,349,1003,332,5003,088,0373,025,2903,134,8053,064,9933,168,1602,697,1252,431,5472,233,2212,261,1591,963,5061,819,8011,810,6951,686,3591,620,5031,522,1531,503,7081,395,0811,418,3631,446,6951,740,205
   > Total Current Liabilities 
792,537
489,796
625,406
710,739
807,260
827,312
927,300
992,508
1,120,292
1,106,468
1,259,220
1,388,894
1,334,827
1,358,974
1,798,640
2,004,026
1,877,533
1,944,050
1,836,448
1,914,264
2,142,000
2,180,200
2,556,200
2,609,300
2,742,100
3,026,200
3,352,100
3,599,400
3,547,400
3,795,900
3,547,200
3,973,100
3,564,600
3,564,6003,973,1003,547,2003,795,9003,547,4003,599,4003,352,1003,026,2002,742,1002,609,3002,556,2002,180,2002,142,0001,914,2641,836,4481,944,0501,877,5332,004,0261,798,6401,358,9741,334,8271,388,8941,259,2201,106,4681,120,292992,508927,300827,312807,260710,739625,406489,796792,537
       Short-term Debt 
319,426
19,270
568,544
587,191
606,433
595,125
592,735
0
0
7,520
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000007,52000592,735595,125606,433587,191568,54419,270319,426
       Short Long Term Debt 
319,426
19,270
568,544
587,191
606,433
595,125
592,735
0
0
7,520
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000007,52000592,735595,125606,433587,191568,54419,270319,426
       Accounts payable 
376,700
341,107
75,941
77,138
73,994
74,062
83,034
92,149
110,987
82,262
77,045
92,528
87,610
1,358,974
101,451
107,786
155,139
127,839
127,534
127,863
195,000
173,600
198,000
126,900
303,900
323,200
363,000
375,900
364,900
351,400
327,900
395,800
413,000
413,000395,800327,900351,400364,900375,900363,000323,200303,900126,900198,000173,600195,000127,863127,534127,839155,139107,786101,4511,358,97487,61092,52877,04582,262110,98792,14983,03474,06273,99477,13875,941341,107376,700
       Other Current Liabilities 
96,411
129,419
186,224
235,166
266,774
325,100
350,086
384,608
394,993
108,758
113,103
122,583
152,299
179,776
151,782
192,541
368,641
284,174
226,358
201,409
399,500
286,100
238,700
218,000
345,400
377,000
391,000
316,200
273,200
648,600
279,300
357,600
31,400
31,400357,600279,300648,600273,200316,200391,000377,000345,400218,000238,700286,100399,500201,409226,358284,174368,641192,541151,782179,776152,299122,583113,103108,758394,993384,608350,086325,100266,774235,166186,224129,41996,411
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
713,333
704,286
872,265
898,394
892,797
898,485
1,164,134
1,504,883
1,474,929
1,188,842
1,375,182
1,458,900
1,168,900
1,092,500
1,067,500
1,807,600
1,515,700
1,526,900
1,614,000
1,602,400
1,574,900
1,810,200
2,636,200
2,559,000
2,559,0002,636,2001,810,2001,574,9001,602,4001,614,0001,526,9001,515,7001,807,6001,067,5001,092,5001,168,9001,458,9001,375,1821,188,8421,474,9291,504,8831,164,134898,485892,797898,394872,265704,286713,333000000000
       Capital Lease Obligations Min Short Term Debt
-319,426
-19,270
-568,544
-587,191
-606,433
-595,125
-592,735
0
0
616,345
611,963
604,539
538,576
532,952
522,067
546,514
581,476
572,856
893,849
558,933
556,700
872,500
847,300
824,600
471,600
789,200
767,600
744,700
808,400
721,300
933,400
1,702,900
1,749,500
1,749,5001,702,900933,400721,300808,400744,700767,600789,200471,600824,600847,300872,500556,700558,933893,849572,856581,476546,514522,067532,952538,576604,539611,963616,34500-592,735-595,125-606,433-587,191-568,544-19,270-319,426
       Other Liabilities 
104,029
103,840
242,592
117,032
112,546
116,635
115,528
117,321
108,853
89,468
92,323
267,726
275,526
499,657
376,418
617,620
297,955
291,958
294,993
296,973
303,300
296,400
245,200
242,900
685,800
0
0
0
0
0
0
0
0
00000000685,800242,900245,200296,400303,300296,973294,993291,958297,955617,620376,418499,657275,526267,72692,32389,468108,853117,321115,528116,635112,546117,032242,592103,840104,029
       Deferred Long Term Liability 
140,695
141,144
140,810
13,599
8,067
9,636
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000009,6368,06713,599140,810141,144140,695
> Total Stockholder Equity
1,156,582
1,500,008
1,671,273
1,791,077
2,028,579
2,401,056
2,686,228
2,906,116
4,435,203
4,723,313
5,069,965
5,253,394
6,085,244
6,461,654
7,519,242
8,133,473
8,686,815
8,980,254
9,196,396
9,530,708
10,100,000
10,907,000
11,933,500
13,029,600
13,912,700
14,432,300
15,470,200
16,512,800
17,580,400
18,546,600
14,774,700
15,630,900
16,409,600
16,409,60015,630,90014,774,70018,546,60017,580,40016,512,80015,470,20014,432,30013,912,70013,029,60011,933,50010,907,00010,100,0009,530,7089,196,3968,980,2548,686,8158,133,4737,519,2426,461,6546,085,2445,253,3945,069,9654,723,3134,435,2032,906,1162,686,2282,401,0562,028,5791,791,0771,671,2731,500,0081,156,582
   Common Stock
2,450
2,459
2,479
2,500
2,512
2,541
2,542
2,551
2,546
2,561
2,565
2,571
2,589
6,461,654
2,601
2,601
2,599
2,588
2,591
2,562
2,500
2,600
2,600
2,600
2,600
2,600
2,600
0
0
0
0
0
0
0000002,6002,6002,6002,6002,6002,6002,5002,5622,5912,5882,5992,6012,6016,461,6542,5892,5712,5652,5612,5462,5512,5422,5412,5122,5002,4792,4592,450
   Retained Earnings Total Equity000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000
   Other Stockholders Equity 
21,173
16,025
-21,753
-25,129
-11,572
-39,743
-4,605
307
659
6,000
-3,201
18,847
-1,973
13,383
-14,121
-40,982
-68,480
-33,302
-25,159
11,537
15,900
11,300
57,500
97,600
800
-13,100
-39,800
0
0
0
0
0
0
000000-39,800-13,10080097,60057,50011,30015,90011,537-25,159-33,302-68,480-40,982-14,12113,383-1,97318,847-3,2016,000659307-4,605-39,743-11,572-25,129-21,75316,02521,173



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue11,020,100
Cost of Revenue-1,530,500
Gross Profit9,489,6009,489,600
 
Operating Income (+$)
Gross Profit9,489,600
Operating Expense-6,625,100
Operating Income4,395,0002,864,500
 
Operating Expense (+$)
Research Development3,630,300
Selling General Administrative1,464,300
Selling And Marketing Expenses-
Operating Expense6,625,1005,094,600
 
Net Interest Income (+$)
Interest Income598,100
Interest Expense-30,600
Other Finance Cost-0
Net Interest Income567,500
 
Pretax Income (+$)
Operating Income4,395,000
Net Interest Income567,500
Other Non-Operating Income Expenses-
Income Before Tax (EBT)248,5009,109,000
EBIT - interestExpense = -30,600
-535,600
-505,000
Interest Expense30,600
Earnings Before Interest and Taxes (EBIT)-279,100
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax248,500
Tax Provision-784,100
Net Income From Continuing Ops-535,600-535,600
Net Income-535,600
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-4,714,000-567,500
 

Technical Analysis of Vertex Pharmaceuticals Incorporated
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Vertex Pharmaceuticals Incorporated. The general trend of Vertex Pharmaceuticals Incorporated is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Vertex Pharmaceuticals Incorporated's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Vertex Pharmaceuticals Incorporated Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Vertex Pharmaceuticals Incorporated.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 385.85 < 407.55 < 444.00.

The bearish price targets are: 378.05 > 374.70 > 368.15.

Know someone who trades $VX1? Share this with them.👇

Vertex Pharmaceuticals Incorporated Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Vertex Pharmaceuticals Incorporated. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Vertex Pharmaceuticals Incorporated Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Vertex Pharmaceuticals Incorporated. The current macd is -9.39921416.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Vertex Pharmaceuticals Incorporated price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Vertex Pharmaceuticals Incorporated. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Vertex Pharmaceuticals Incorporated price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Vertex Pharmaceuticals Incorporated Daily Moving Average Convergence/Divergence (MACD) ChartVertex Pharmaceuticals Incorporated Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Vertex Pharmaceuticals Incorporated. The current adx is 15.95.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Vertex Pharmaceuticals Incorporated shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Vertex Pharmaceuticals Incorporated Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Vertex Pharmaceuticals Incorporated. The current sar is 440.27.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Vertex Pharmaceuticals Incorporated Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Vertex Pharmaceuticals Incorporated. The current rsi is 29.11. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Vertex Pharmaceuticals Incorporated Daily Relative Strength Index (RSI) ChartVertex Pharmaceuticals Incorporated Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Vertex Pharmaceuticals Incorporated. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Vertex Pharmaceuticals Incorporated price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Vertex Pharmaceuticals Incorporated Daily Stochastic Oscillator ChartVertex Pharmaceuticals Incorporated Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Vertex Pharmaceuticals Incorporated. The current cci is -271.155596.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Vertex Pharmaceuticals Incorporated Daily Commodity Channel Index (CCI) ChartVertex Pharmaceuticals Incorporated Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Vertex Pharmaceuticals Incorporated. The current cmo is -54.7816607.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Vertex Pharmaceuticals Incorporated Daily Chande Momentum Oscillator (CMO) ChartVertex Pharmaceuticals Incorporated Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Vertex Pharmaceuticals Incorporated. The current willr is -99.26739927.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Vertex Pharmaceuticals Incorporated Daily Williams %R ChartVertex Pharmaceuticals Incorporated Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Vertex Pharmaceuticals Incorporated.

Vertex Pharmaceuticals Incorporated Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Vertex Pharmaceuticals Incorporated. The current atr is 11.88.

Vertex Pharmaceuticals Incorporated Daily Average True Range (ATR) ChartVertex Pharmaceuticals Incorporated Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Vertex Pharmaceuticals Incorporated. The current obv is 211.00.

Vertex Pharmaceuticals Incorporated Daily On-Balance Volume (OBV) ChartVertex Pharmaceuticals Incorporated Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Vertex Pharmaceuticals Incorporated. The current mfi is 31.79.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Vertex Pharmaceuticals Incorporated Daily Money Flow Index (MFI) ChartVertex Pharmaceuticals Incorporated Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Vertex Pharmaceuticals Incorporated.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-10 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-13 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-19 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-27 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-12-30 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-06 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-10 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-15 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-16 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-22 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-01-23 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-01-24 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-01-28 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-06 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-07 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-10 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-12 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-13 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-19 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-21 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-26 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-28 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-03 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-04 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-05 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-07 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-10 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-12 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-13 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-17 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-24 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-25 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-26 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-28 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-31 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-02 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-10 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-14 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-16 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-24 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-30 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-07 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-08 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Vertex Pharmaceuticals Incorporated Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Vertex Pharmaceuticals Incorporated based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.108
Ma 20Greater thanMa 50426.335
Ma 50Greater thanMa 100446.351
Ma 100Greater thanMa 200435.308
OpenGreater thanClose383.600
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Vertex Pharmaceuticals Incorporated with someone you think should read this too:
  • Are you bullish or bearish on Vertex Pharmaceuticals Incorporated? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Vertex Pharmaceuticals Incorporated? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Vertex Pharmaceuticals Incorporated

I send you an email if I find something interesting about Vertex Pharmaceuticals Incorporated.


Comments

How you think about this?

Leave a comment

Stay informed about Vertex Pharmaceuticals Incorporated.

Receive notifications about Vertex Pharmaceuticals Incorporated in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.